Abstract:Cerebrospinal fluid (CSF) is a body fluid that can be used for the diagnosis of various diseases. However, CSF collection requires an invasive and painful procedure called a lumbar puncture (LP). This procedure is applied to any patient with a known risk of central nervous system (CNS) damage or neurodegenerative disease, regardless of their age range. Hence, this can be a very painful procedure, especially in infants and elderly patients. On the other hand, the detection of disease biomarkers in CSF makes diagnoses as accurate as possible. This review aims to explore novel electrochemical biosensing platforms that have impacted biomedical science. Biosensors have emerged as techniques to accelerate the detection of known biomarkers in body fluids such as CSF. Biosensors can be designed and modified in various ways and shapes according to their ultimate applications to detect and quantify biomarkers of interest. This process can also significantly influence the detection and diagnosis of CSF. Hence, it is important to understand the role of this technology in the rapidly progressing field of biomedical science.

What problem does this paper attempt to address?

### What problems does this paper attempt to solve? This paper aims to explore the latest progress of cerebrospinal fluid (CSF) biosensors, especially how to bridge the gap from early diagnosis to rare disease detection through these sensors. Specifically, the study attempts to solve the following key problems: 1. **Problems with invasive CSF collection**: - CSF collection usually requires lumbar puncture (LP), which is an invasive and painful procedure, especially more uncomfortable for infants and elderly patients. - Although LP is the main current method of CSF collection, it has various risks and complications, such as severe headache, infection, and bleeding. 2. **Limitations of traditional laboratory detection methods**: - Currently, techniques used to detect biomarkers in CSF, such as mass spectroscopy, enzyme - linked immunosorbent assay (ELISA), Western Blotting, and high - performance liquid chromatography (HPLC), are accurate but time - consuming, costly, and require complex sample pretreatment. - These methods have limited sensitivity and specificity in early disease detection, especially in the case of low - concentration biomarkers. 3. **The need for new non - invasive CSF biosensors**: - The research emphasizes the importance of developing new non - invasive, point - of - care CSF biosensors to improve detection speed, accuracy, and sensitivity. - New biosensors can achieve rapid and high - precision detection of specific biomarkers in CSF through electrochemical, optical, piezoelectric, and other methods, thus providing new tools for early diagnosis and rare disease detection. 4. **Improving the clinical application of CSF biomarker detection**: - By improving the design and technology of biosensors, biomarkers in CSF can be detected more effectively, thereby enhancing the diagnosis and treatment effects of neurodegenerative diseases, cancer, and other central nervous system diseases. - Especially in terms of early diagnosis, these sensors are expected to significantly shorten the detection time and improve the diagnostic accuracy, thus improving the prognosis of patients. ### Summary The core objective of this paper is to explore and evaluate the development of new CSF biosensors, especially their application potential in early diagnosis and rare disease detection, in order to overcome the limitations of existing methods and provide more effective and convenient solutions for clinical practice.

Advancements in Cerebrospinal Fluid Biosensors: Bridging the Gap from Early Diagnosis to the Detection of Rare Diseases

Identification of Glycoproteins in Human Cerebrospinal Fluid with a Complementary Proteomic Approach

Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders.

Advances in the development paradigm of biosample‐based biosensors for early ultrasensitive detection of alzheimer’s disease

Novel CSF Biomarkers Tracking Autoimmune Inflammatory and Neurodegenerative Aspects of CNS Diseases

Advancements in Brain Research: The In Vivo/In Vitro Electrochemical Detection of Neurochemicals

Advancements in Electrochemical Biosensing of Cardiovascular Disease Biomarkers

Advancements in electrochemical immunosensors towards point-of-care detection of cardiac biomarkers

Implantable Sensor for Detecting Changes in the Loss Tangent of Cerebrospinal Fluid

Demyelination detection in CSF based on electrochemical monitoring of myelin basic protein in comparison between Apta vs. Immuno sensing strategies

Neurons as biosensors for discriminating neurological disorders in a brain-on-chip platform: Application to Alzheimer s Disease using patient CSF

Navigating the Alzheimer's Biomarker Landscape: A Comprehensive Analysis of Fluid-Based Diagnostics

CRISPR-Driven Biosensors: A New Frontier in Rapid and Accurate Disease Detection

Biosensors Designed for Clinical Applications

Tau, Glial Fibrillary Acidic Protein, and Neurofilament Light Chain as Brain Protein Biomarkers in Cerebrospinal Fluid and Blood for Diagnosis of Neurobiological Diseases

Advances in Electrochemical Nano-Biosensors for Biomedical and Environmental Applications: From Current Work to Future Perspectives

In vitro selection of human cerebrospinal fluid-specific aptamers using clinical samples

Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease: Current Evidence and Future Perspectives

Applications of cerebrospinal fluid circulating tumor cells and circulating tumor-derived DNA in diagnosis, prognosis, and personalized treatment of CNS metastases

Challenges and strategies faced in the electrochemical biosensing analysis of neurochemicals in vivo: A review

Assessment of CSF Dynamics Using Infusion Study: Tips and Tricks